Skip to main content

Advertisement

SpringerLink
Log in

GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma

  • Clinical Guides in Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma (STS) in children and adolescents. In Spain the annual incidence is 4.4 cases per million children < 14 years. It is an uncommon neoplasm in adults, but 40% of RMS are diagnosed in patients over 20 years of age, representing 1% of all STS in this age group. RMS can appear anywhere in the body, with some sites more frequently affected including head and neck, genitourinary system and limbs. Assessment of a patient with suspicion of RMS includes imaging studies (MRI, CT, PET-CT) and biopsy. All patients with RMS should receive chemotherapy, either at diagnosis in advanced or metastatic stages, or after initial resection in early local stages. Local control includes surgery and/or radiotherapy depending on site, stage, histology and response to chemotherapy. This guide provides recommendations for diagnosis, staging and treatment of this neoplasm.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. https://www.skion.nl/workspace/uploads/Protocol-EpSSG-RMS-2005-1-3-May-2012_1.pdf.

  2. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;15(33):139–44.

    Article  Google Scholar 

  3. Garcia del Muro X, de Alava E, Artigas V, Bague S, Braña A, Cubedo R, Spanish Group for Research on Sarcoma, et al. Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS). Cancer Chemother Pharmacol. 2016;77:133–46.

    Article  CAS  PubMed  Google Scholar 

  4. Pardo Romaguera E, Muñoz López A, Valero Poveda S, Porta Cebolla S, Barreda Reines MS, Fernández Delgado R, et al. Cáncer infantil en España. Estadísticas 1980–2018. Registro Español de Tumores infantiles (RETI-SEHOP). 2019.

  5. Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995 National Cancer Institute SEER Program. Bethesda: NIH Pub No. 99-4649; 1999.

    Google Scholar 

  6. Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirlaque MD, et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer. 2013;49:684–95.

    Article  CAS  PubMed  Google Scholar 

  7. Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2600 patients. J Clin Oncol. 2009;27:3391–7.

    Article  PubMed  Google Scholar 

  8. Nakata K, Ito Y, Magadi W, Bonaventure A, Stiller CA, Katanoda K, et al. Childhood cancer incidence and survival in Japan and England: a population-based study (1993–2010). Cancer Sci. 2018;109:422–34.

    Article  CAS  PubMed  Google Scholar 

  9. Stiller CA, Parkin DM. International variations in the incidence of childhood soft-tissue sarcomas. Paediatr Perinat Epidemiol. 1994;8:107–19.

    Article  CAS  PubMed  Google Scholar 

  10. Nichols KE, Malkin D, Garber JE, Li FP. Germ line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomark Prev. 2001;10:83–7.

    CAS  Google Scholar 

  11. Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, et al. Rhabdomyosarcoma. Nat Rev Dis Primers. 2019;5:1.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer J Clin. 2019;69:7–34.

    Article  Google Scholar 

  13. Freling NJM, Merks JHM, Saeed P, Balm AJM, Bras J, Pieters BR, et al. Imaging findings in craniofacial childhood rhabdomyosarcoma. Pediatr Radiol. 2010;20(40):1723–38.

    Article  Google Scholar 

  14. McCarville MB, Spunt SL, Pappo AS. Rhabdomyosarcoma in pediatric patients: the good, the bad and the unusual. Am J Roentgenol. 2001;176:1563–9.

    Article  CAS  Google Scholar 

  15. Hayes-Jordan A, Andrassy R. Rhabdomyosarcoma in children. Curr Opin Pediatr. 2009;21:373–8.

    Article  PubMed  Google Scholar 

  16. Park K, van Rijn R, McHugh K. The role of radiology in paediatric soft tissue sarcomas. Cancer Imaging. 2008;8:102–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Inarejos Clemente EJ, Navallas M, Martínez B, de la Torre I, Suñol M, Munuera Del Cerro J, Torner F, et al. MRI of rhabdomyosarcoma and other soft-tissue sarcomas in children. Radiographics. 2020;40:791–814.

    Article  PubMed  Google Scholar 

  18. Saboo SS, Krajewski KM, Zukotynski K, Howard S, Jagannathan JP, Hornick JL, et al. Imaging features of primary and secondary adult rhabdomyosarcoma. Am J Roentgenol. 2012;199:W694-703.

    Article  Google Scholar 

  19. van Vliet M, Kliffen M, Krestin GP, van Dijke CF, Vliet M, Kliffen M, et al. Soft tissue sarcomas at a glance: clinical, histological, and MR imaging features of malignant extremity soft tissue tumors. Eur Radiol. 2009;19:1499–511.

    Article  PubMed  Google Scholar 

  20. El-Kholy E, El Nadi E, Hafez H, Ahmed S, Younes A, El-Kenanii N, et al. Added predictive value of 18F-FDG PET/CT for pediatric rhabdomyosarcoma. Nucl Med Commun. 2019;40:898–904.

    Article  CAS  PubMed  Google Scholar 

  21. Sa R, Liu D, Zhao H, Hou S, Lin Q, Guan F. Utility of [(18)F] fluoro-deoxyglucose positron emission tomography/computed tomography for staging and therapy response evaluation in pediatric rhabdomyosarcoma: a case series and literature review. Front Med (Lausanne). 2020;7:281.

    Article  Google Scholar 

  22. Berger-Richardson D, Swallow CJ. Needle tract seeding after percutaneous biopsy of sarcoma: risk/benefit considerations. Cancer. 2017;123:560–7.

    Article  PubMed  Google Scholar 

  23. Barrientos-Ruiz I, Ortiz-Cruz EJ, Serrano-Montilla J, Bernabeu-Taboada D, Pozo-Kreilinger JJ. Are biopsy tracts a concern for seeding and local recurrence in sarcomas? Clini Orthop Relat Res. 2017;475(2):511–8.

    Article  Google Scholar 

  24. Chowdhury T, Barnacle A, Haque S, Sebire N, Gibson S, Anderson J, et al. Ultrasound-guided core needle biopsy for the diagnosis of rhabdomyosarcoma in childhood. Pediatr Blood Cancer. 2009;53(3):356–60.

    Article  PubMed  Google Scholar 

  25. Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol. 2013;20:387–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Alaggio R, Zhang L, Sung YS, Huang SC, Chen CL, Bisogno G, et al. A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am J Surg Pathol. 2016;40:224–35.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Mosquera JM, Sboner A, Zhang L, Kitabayashi N, Chen CL, Sung YS, et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer. 2013;52:538–50.

    Article  CAS  PubMed  Google Scholar 

  28. Agaram NP, LaQuaglia MP, Alaggio R, Zhang L, Fujisawa Y, Ladanyi M, et al. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Mod Pathol. 2019;32:27–36.

    Article  CAS  PubMed  Google Scholar 

  29. Le Loarer F, Cleven AHG, Bouvier C, Castex MP, Romagosa C, Moreau A, et al. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Mod Pathol. 2020;33:404–19.

    Article  PubMed  CAS  Google Scholar 

  30. Hibbitts E, Chi YY, Hawkins DS, Barr FG, Bradley JA, Dasgupta R, et al. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: a report from the Children’s Oncology Group. Cancer Med. 2019;8:6437–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Freling NJM, Merks JHM, Saeed P, Balm AJM, Bras J, Pieters BR, et al. Imaging findings in craniofacial childhood rhabdomyosarcoma. Pediatr Radiol. 2010;40:1723–38.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Jawad N, McHugh K. The clinical and radiologic features of paediatric rhabdomyosarcoma. Pediatr Radiol. 2019;49:1516–23.

    Article  PubMed  Google Scholar 

  33. Norman G, Fayter D, Lewis-Light K, Chisholm J, McHugh K, Levine D, et al. An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review. BMJ Open. 2015;5:e006030.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Wagner LM, Kremer N, Gelfand MJ, Sharp SE, Turpin BK, Nagarajan R, et al. Detection of lymph node metastases in pediatric and adolescent/young adult sarcoma: Sentinel lymph node biopsy versus fludeoxyglucose positron emission tomography imaging-A prospective trial. Cancer. 2017;123:155–60.

    Article  CAS  PubMed  Google Scholar 

  35. Bethesda MD. PDQ Childhood Rhabdomyosarcoma Treatment. National Cancer Institute. 2020. https://www.cancer.gov/types/softtissuesarcoma/hp/rhabdomyosarcoma-treatment-pdq. Accessed 12 July 2020.

  36. Lim HJ, Johnny Ong CA, Tan JW, Ching Teo MC. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: a systematic review. Crit Rev Oncol Hematol. 2019;143:1–13.

    Article  PubMed  Google Scholar 

  37. Völker T, Denecke T, Steffen I, Misch D, Schönberger S, Plotkin M, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007;25:5435–41.

    Article  PubMed  Google Scholar 

  38. Gennaro N, Marrari A, Renne SL, Cananzi FCM, Quagliuolo VL, Di Brina L, et al. Multimodality imaging of adult rhabdomyosarcoma: the added value of hybrid imaging. Br J Radiol. 2020;93:20200250.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Terwisscha van Scheltinga SEJ, Wijnen M, Martelli H, Rogers T, Mandeville H, Gaze MN, et al. Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG-RMS2005 study. Cancer Med. 2020;9:7580–9.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Federico SM, Spunt SL, Krasin MJ, Billup CA, Wu J, Shulkin B, et al. Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma. Pediatr Blood Cancer. 2013;60:1128–34.

    Article  PubMed  Google Scholar 

  41. National Cancer Institute. Sentinel Lymph Node Biopsy. 2011

  42. Parida L, Morrisson GT, Shammas A, Hossain AKM, McCarville MB, Gerstle T, et al. Role of lymphoscintigraphy and sentinel lymph node biopsy in the management of pediatric melanoma and sarcoma. Ped Surg Int. 2012;28:571–8.

    Article  Google Scholar 

  43. Rogers T, Smeele L, Scheltinga STV, Corti FD, Guillén Burrieza G, Smeulders N, et al. Surgery guidelines rhabdomyosarcoma, long version, FaRMS protocol, EpSSG [Internet]. https://www.epssgassociation.it/en/.

  44. Weiss AR, Lyden ER, Anderson JR, Hawkins DS, Spunt SL, Walterhouse DO, et al. Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol. 2013;31:3226.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Lawrence W, Anderson JR, Gehan EA, Maurer H. Pretreatment TNM staging of childhood rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Cancer. 1997;80:1165–70.

    Article  PubMed  Google Scholar 

  46. Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol. 2012;30:1670–7.

    Article  PubMed  Google Scholar 

  47. Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AD, Paidas CN, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children’s oncology group study D9803. J Clin Oncol. 2009;27:5182–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, et al. Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Childrens Oncology Group. J Clin Oncol. 2018;36:2770–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Oberlin O, Rey A, Sanchez de Toledo J, Jenney JEM, Scopinaro M, Bergeron C, et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol. 2012;30:2457–65.

    Article  CAS  PubMed  Google Scholar 

  50. Ferrari A, Bisogno G, Casanova M, Meazza C, Piva L, Cecchetto G, et al. Paratesticular rhabdomyosarcoma: report from the Italian and German Cooperative Group. J Clin Oncol. 2002;20:449–55.

    Article  CAS  PubMed  Google Scholar 

  51. Bisogno G, Jenney M, Bergeron C, Gallego Melcon S, Ferrari A, Oberlin O, et al. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol. 2018;19:1061–71.

    Article  CAS  PubMed  Google Scholar 

  52. Gallego S, Zanetti I, Orbach D, Ranchere D, Shipley J, Zin A, et al. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer. 2018;124:3201–9.

    Article  CAS  PubMed  Google Scholar 

  53. Bisogno G, de Salvo GL, Bergeron C, Gallego G, Merks JM, Kelsey A, et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:1566–75.

    Article  CAS  PubMed  Google Scholar 

  54. Cecchetto G, Bisogno G, De Corti F, Dall’Igna P, Inserra A, Ferrari A, et al. Biopsy or debulking surgery as initial surgery for locally advanced rhabdomyosarcomas in children?: The experience of the Italian Cooperative Group studies. Cancer. 2007;110:2561–7.

    Article  PubMed  Google Scholar 

  55. Schmidt A, Warmann SW, Eckert F, Ellerkamp V, Schaefer J, Blumenstock G, et al. The role of reconstructive surgery and brachytherapy in pediatric bladder/prostate rhabdomyosarcoma. J Urol. 2020;204:825–34.

    Article  PubMed  Google Scholar 

  56. Chargari C, Haie-Meder C, Guérin F, Minard-Colin V, de Lambert G, Mazeron R, et al. Brachytherapy combined with surgery for conservative treatment of children with bladder neck and/or prostate. Int J Radiat Oncol Biol Phys. 2017;98:352–9.

    Article  PubMed  Google Scholar 

  57. Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer. 2003;98:571–80.

    Article  PubMed  Google Scholar 

  58. Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, Carli M, Anderson JR. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008;26:2384–9.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Bergamaschi L, Bertulli R, Casanova M, Provenzano S, Chiaravalli S, Gasparini P, et al. Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single-center series. Med Oncol. 2019;36:59.

    Article  PubMed  Google Scholar 

  60. Malempati S, Weigel BJ, Chi YY, Tian J, Anderson JR, Parham DM, et al. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: a report from the Children’s Oncology Group. Cancer. 2019;125:290–7.

    Article  CAS  PubMed  Google Scholar 

  61. McDowell HP, Foot AB, Ellershaw C, Machin D, Giraud C, Bergeron C. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98. Eur J Cancer. 2010;46:1588–95.

    Article  PubMed  Google Scholar 

  62. Bergeron C, Thiesse P, Rey A, Orbach D, Boutard P, Thomas C, et al. Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease. Eur J Cancer. 2008;44:427–31.

    Article  CAS  PubMed  Google Scholar 

  63. Peinemann F, Kröger N, Bartel C, Grouven U, Pittler M, Erttmann R, et al. High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma—a systematic review. PLoS ONE. 2011;6:e17127.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Arush MB, Minard-Colin V, Mosseri V, Defachelles AS, Bergeron C, Algret N, et al. Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma? Eur J Cancer. 2015;51:193–201.

    Article  PubMed  Google Scholar 

  65. Mohan AC, Venkatramani R, Okcu MF, Nuchtern JG, Vasudevan SA, Mahajan A, et al. Local therapy to distant metastatic sites in stage IV rhabdomyosarcoma. Pediatr Blood Cancer. 2018;65:e26859.

    Article  Google Scholar 

  66. Liu AK, Stinauer M, Albano E, Greffe B, Tello T, Maloney K. Local control of metastatic sites with radiation therapy in metastatic Ewing sarcoma and rhabdomyosarcoma. Pediatr Blood Cancer. 2011;57:169–71.

    Article  PubMed  Google Scholar 

  67. Cameron A, Chisholm J, Elze MC, Casanova M, Geoerger B, Gaze M. Role of radiotherapy to primary/metastatic sites in pediatric patients with metastatic rhabdomyosarcoma in the BERNIE study. J Clin Oncol. 2017;35(suppl):10541.

    Article  Google Scholar 

  68. Schoot RA, McHugh K, Van Rijn RR, Kremer LCM, Chisholm JC, Caron HN, et al. Response assessment in pediatric rhabdomyosarcoma: can response evaluation criteria in solid tumors replace three-dimensional volume assessments? Radiology. 2013;269:870–8.

    Article  PubMed  Google Scholar 

  69. Orsatti G, Beltrame V, Crimì F, Frigo AC, Bisogno G, Stramare R. Radiologic response assessment in pediatric soft tissue sarcoma: computed-assisted volume evaluation. J Pediatr. 2017;182:327-334.e2.

    Article  PubMed  Google Scholar 

  70. Rosenberg AR, Anderson JR, Lyden E, Rodeberg DA, Wolden SL, Kao SC, et al. Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children’s Oncology Group. Eur J Cancer. 2014;50(4):816–23.

    Article  PubMed  Google Scholar 

  71. Casey DL, Wexler LH, Fox JJ, Dharmarajan KV, Schoder H, Price AN, et al. Predicting outcome in patients with rhabdomyosarcoma: role of (18)FDG positron emission tomography. Int J Radiat Oncol Biol Phys. 2014;90:1136–42.

    Article  PubMed  Google Scholar 

  72. Voss SD. Functional and anatomical imaging in pediatric oncology: which is best for which tumors. Pediatr Radiol. 2019;49:1534–44.

    Article  PubMed  Google Scholar 

  73. Pourmehdi Lahiji A, Jackson T, Nejadnik H, von Eyben R, Rubin D, Spunt SL, et al. Association of tumor [(18)F]FDG activity and diffusion restriction with clinical outcomes of rhabdomyosarcomas. Mol Imaging Biol. 2019;21:591–8.

    Article  PubMed  Google Scholar 

  74. Pappo AS, Anderson JR, Crist WM, Wharam MD, Breitfeld PP, Hawkins DS, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol. 1999;17:3487–93.

    Article  CAS  PubMed  Google Scholar 

  75. Lager JJ, Lyden ER, Pappo AS, Meyer WH, Breitfeld PP. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol. 2006;24:3415–22.

    Article  PubMed  Google Scholar 

  76. Mascarenhas L, Lyden ER, Breitfeld PP, Walterhouse DO, Donaldson SS, Paidas CN, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2010;28:4658–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Defachelles AS, Bogart E, Casanova M, Merks H, Bisogno G, Calareso G, et al. Randomized phase 2 trial of the combination of vincristine and irinotecan with or without temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS ASCO 2019 (Abstract #250271). J Clin Oncol. 2019. https://doi.org/10.1200/JCO.2019.37.15_suppl.10000.

    Article  Google Scholar 

  78. Chisholm JC, Machin D, McDowell H, McHugh K, Ellershaw C, Jenney M, et al. Efficacy of carboplatin given in a phase II window study to children and adolescents with newly diagnosed of metastatic soft tissue sarcoma. Eur J Cancer. 2007;43:2537–44.

    Article  CAS  PubMed  Google Scholar 

  79. Casanova M, Ferrari A, Bisogno G, Merks JHM, De Salvo GL, Meazza C, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer. 2004;101:1664–71.

    Article  CAS  PubMed  Google Scholar 

  80. Saylors RL, Stine KC, Sullivan J, Kepner JL, Bernstein ML, Harris MB, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19:3463–9.

    Article  CAS  PubMed  Google Scholar 

  81. Hayes-Jordan A, Doherty DK, West SD, Raney RB, Blakely ML, Cox CS, et al. Outcome after surgical resection of recurrent rhabdomyosarcoma. J Pediatr Surg. 2006;41:633–8.

    Article  PubMed  Google Scholar 

  82. Dantonello TM, Int-Veen C, Schuck A, Seitz G, Leuschner I, Nathrath M, et al. Survival following disease recurrence of primary localized alveolar rhabdomyosarcoma: recurrent alveolar rhabdomyosarcoma outcomes. Pediatr Blood Cancer. 2013;60:1267–73.

    Article  PubMed  Google Scholar 

  83. Susa M, Kikuta K, Nakayama R, Nishimoto K, Horiuchi K, Oguro S, et al. CT guided cryoablation for locally recurrent or metastatic bone and soft tissue tumor: Initial experience. BMC Cancer [Internet]. 2016;16:798.

    Article  Google Scholar 

  84. Grilley-Olson JE, Webber NP, Demos DS, Christensen JD, Kirsch DG. Multidisciplinary management of oligometastatic soft tissue sarcoma. Am Soc Clin Oncol Educ B. 2018;38:939–48.

    Article  Google Scholar 

  85. Dantonello TM, Int-Veen C, Winkler LI, Schuck A, Schmidt BF, et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma tobias. J Clin Oncol. 2008;26:406–13.

    Article  PubMed  Google Scholar 

  86. Hammond WJ, Farber BA, Price AP, Wolden SL, Heaton TE, Wexler LH, et al. Paratesticular rhabdomyosarcoma: importance of initial therapy. J Pediatr Surg. 2017;52:304–8.

    Article  PubMed  Google Scholar 

  87. Bradley JA, Indelicato DJ, Uezono H, Morris CG, Sandler E, de Soto H, et al. Patterns of failure in parameningeal alveolar rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2020;107:325–33.

    Article  PubMed  Google Scholar 

  88. Vaarwerk B, Mallebranche C, Affinita MC, van der Lee JH, Ferrari A, Chisholm JC, et al. Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? Eur Exp Cancer. 2020;125:823–31.

    Google Scholar 

  89. Bate J, Wingrove J, Donkin A, Taylor R, Whelan J. Patient perspectives on a national multidisciplinary team meeting for a rare cancer. Eur J Cancer Care. 2019;28:12971.

    Article  Google Scholar 

  90. Blay JY, Sleijfer S, Schöffski P, Kawai A, Brodowicz T, Demetri GD, Maki RG. International expert opinion on patient-tailored management of soft tissue sarcomas. Eur J Cancer. 2014;50:679–89.

    Article  PubMed  Google Scholar 

  91. Punyko JA, Gurney JG, Scott Baker K, Hayashi RJ, Hudson MM, Liu Y, et al. Physical impairment and social adaptation in adult survivors of childhood and adolescent rhabdomyosarcoma: a report from the Childhood Cancer Survivors Study. Psychooncology. 2007;16:26–37.

    Article  PubMed  Google Scholar 

  92. Vaarwerk B, Schoot RA, Maurice-Stam H, Slater O, Hartley B, Saeed P, et al. Psychosocial well-being of long-term survivors of pediatric head-neck rhabdomyosarcoma. Pediatr Blood Cancer. 2019;66:e27498.

    Article  PubMed  Google Scholar 

  93. Tonning Olsson I, Brinkman TM, Wang M, Ehrhardt MJ, Banerjee P, Mulrooney DA, et al. Neurocognitive and psychosocial outcomes in adult survivors of childhood soft-tissue sarcoma: a report from the St Jude Lifetime Cohort. Cancer. 2020;126:1576–84.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Ms. Helena Kruyer for English correction. GEIS (Grupo Español de Investigación en Sarcomas): S. Gallego, D. Bernabeu, N. Hindi, C. Mata, C. Marquez, J. Orcajo, G. Ramírez, C. Romagosa, C. Valverde, R. Vergés. SEHOP (Sociedad Española de Hematología y Oncología Pediátrica): S. Gallego, A. Juan Ribelles, C. Marquez, C. Mata, G. Ramírez, D. Ruano, P. Rubio.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Pediatric Oncology and Hematology, Vall D’Hebron University Hospital, Pº Vall d’Hebron 119-129, 08035, Barcelona, Spain

    S. Gallego

  2. Radiodiagnostic Department, Hospital Universitario La Paz (Madrid), Madrid, Spain

    D. Bernabeu

  3. Pediatric and Perinatal Pathology Unit, Pathology Department, Vall D’Hebron University Hospital (Barcelona), Barcelona, Spain

    M. Garrido-Pontnou

  4. Surgical Oncology Unit, Pediatric Surgery Department, Vall D’Hebron University Hospital (Barcelona), Barcelona, Spain

    G. Guillen

  5. Sarcoma Unit, University Hospital Fundación Jimenez Díaz (Madrid), Madrid, Spain

    N. Hindi

  6. Pediatric Oncology and Hematology, University Hospital La Fe (Valencia), Valencia, Spain

    A. Juan-Ribelles

  7. Pediatric Oncology and Hematology, Pediatric Hospital Virgen del Rocío (Sevilla), Sevilla, Spain

    C. Márquez & G. Ramírez

  8. Pediatric Oncology and Hematology, Gregorio Marañón University Hospital (Madrid), Madrid, Spain

    C. Mata

  9. Nuclear Medicine Department, Gregorio Marañón University Hospital (Madrid), Madrid, Spain

    J. Orcajo

  10. Radiotherapy Department, Vall D’Hebron University Hospital (Barcelona), Barcelona, Spain

    M. Ramos

  11. Pathology Department, Vall D’Hebron University Hospital (Barcelona), Barcelona, Spain

    C. Romagosa

  12. Pediatric Oncology and Hematology, Hospital Niño Jesús (Madrid), Madrid, Spain

    D. Ruano

  13. Pediatric Oncology and Hematology, University Hospital La Paz (Madrid), Madrid, Spain

    P. Rubio

  14. Medical Oncology, Vall D’Hebron University Hospital, Pº Vall d’Hebron 119-129, 08035, Barcelona, Spain

    R. Vergés

  15. Radiotherapy Department, Vall D’Hebron University Hospital (Barcelona), Barcelona, Spain

    C. Valverde

Authors
  1. S. Gallego
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Bernabeu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Garrido-Pontnou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Guillen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Hindi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Juan-Ribelles
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Márquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Mata
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. Orcajo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G. Ramírez
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M. Ramos
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C. Romagosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. D. Ruano
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. P. Rubio
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. R. Vergés
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. C. Valverde
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

GEIS (Grupo Español de Investigación en Sarcomas), SEHOP (Sociedad Española de Hematología y Oncología Pediátrica)

  • S. Gallego
  • , D. Bernabeu
  • , N. Hindi
  • , C. Mata
  • , C. Marquez
  • , J. Orcajo
  • , G. Ramírez
  • , C. Romagosa
  • , C. Valverde
  • , R. Vergés
  • , A. Juan-Ribelles
  • , D. Ruano
  •  & P. Rubio

Contributions

All authors: conceptualization, methodology, writing and editing, approval of the final version of the manuscript.

Corresponding authors

Correspondence to S. Gallego or C. Valverde.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gallego, S., Bernabeu, D., Garrido-Pontnou, M. et al. GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma. Clin Transl Oncol 23, 2460–2473 (2021). https://doi.org/10.1007/s12094-021-02654-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-021-02654-1

Keywords

Search

Navigation